SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update

MDNA11 Phase 1/2 ABILITY-1 completes 152-patient enrollment and demonstrates 40% objective response rate (ORR) and 80% disease control rate (DCR) in biomarker-enriched gastrointestinal cancersThe melanoma data were similarly encouraging, with ORRs of 30% and 38% in secondary and primary ICI-resista…

MDNA

Related stories